Early Data Show Epcoritamab Induces Responses in High-Risk DLBCL in First Line
Cancer Network,
High response rates were noted in a phase 1/2 trial of the bispecific antibody epcoritamab to treat first-line, high-risk…
High response rates were noted in a phase 1/2 trial of the bispecific antibody epcoritamab to treat first-line, high-risk…
The addition of subcutaneous epcoritamab to standard-of-care R-CHOP demonstrated clinically meaningful response in the first-line…